

**Product Name**

Name: Phytohaemagglutinin-M (PHA-M), Liquid

Cat. No.: C3545-0005

Size: 5 mL

**Product Description**

Phytohaemagglutinin is a lectin extracted from red kidney beans (*Phaseolus vulgaris*). The protein consists of two molecular species, leucoagglutinin (PHA-L) and erythroagglutinin (PHA-E). Each of the proteins contains a family of five isolectins, each being a tetramer held together by noncovalent forces. PHA-M is the mucoprotein form and is a crude extract used for the stimulation of cell proliferation in lymphocyte culture. PHA-M also has a powerful erythro-agglutinating property, and it was originally used for separating leukocytes from whole blood.

PHA-M is a sterile, frozen solution of an aqueous extract from selected red kidney beans.

**Procedure**

1. Remove from storage at  $-20^{\circ}\text{C}$ , read the label, inspect the packaging and appearance of the solution, and allow it to thaw at  $2-8^{\circ}\text{C}$  or room temperature.
2. After thawing, the solution contains 2 mg of protein per milliliter.
3. In a sterile environment, inoculate approximately 0.5 mL of heparin-anticoagulated whole blood into a glass or plastic culture container, add 5 mL of culture medium, and achieve a concentration of approximately  $10^6/\text{mL}$  viable cells per milliliter.
4. Incubate in a  $37^{\circ}\text{C}$ , 5%  $\text{CO}_2$  incubator for 72 hours.
5. Recommended dosage: Add 0.1-0.4 mL of Phytohaemagglutinin (PHA) per 100 mL of culture medium.

**Storage and Stability**

The product should be kept at  $-20^{\circ}\text{C}$ .

Avoid repeated freeze and thaw cycle.

Avoid direct light exposure.

Shelf life: 18 months from date of manufacture

**Note**

- For in vitro diagnostic use. PHA-M is not intended for therapeutic use.
- Use of VivaCell PHA-M does not guarantee the successful outcome of any diagnostic testing.
- Do not use PHA-M beyond the expiration date indicated on the product label.

**Quality Control**

PHA-M is tested for sterility. In addition, mitotic stimulation is evaluated using primary human peripheral blood lymphocytes.

**Manufacturer**

Shanghai Dr. Cell Co., Ltd.

**Issue Date**

Jun 1<sup>st</sup>, 2025

Revision Date: Dec.24th, 2025

**Precaution and Disclaimer**

For research use only, not for clinical diagnosis, and treatment.

